Related Experiment Videos
Initial results from a longitudinal international surveillance programme for anidulafungin (2003)
Shawn A Messer1, Jeffrey T Kirby, Helio S Sader
1The JONES Group/JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA. shawn-messer@jmilabs.com
The Journal of Antimicrobial Chemotherapy
|November 27, 2004
Summary
Anidulafungin demonstrates potent in vitro activity against a broad spectrum of yeast and mould pathogens. This echinocandin shows significant efficacy, particularly against common Candida species and Aspergillus, supporting its role in treating invasive fungal infections.
Area of Science:
- Clinical Mycology
- Antifungal Drug Discovery
- Infectious Diseases
Background:
- Invasive fungal infections pose a significant threat, necessitating effective antifungal agents.
- Echinocandins, such as anidulafungin, represent a crucial class of antifungals.
- Understanding the in vitro activity spectrum of anidulafungin is vital for guiding clinical use.
Purpose of the Study:
- To assess the in vitro antifungal activity of anidulafungin against a large, diverse collection of clinical yeast and mould isolates.
- To compare the efficacy of anidulafungin with established antifungal agents across various fungal species.
- To provide international surveillance data on anidulafungin's performance against medically important fungi.
Main Methods:
- A longitudinal study involving 880 yeast and 68 mould clinical isolates from North America, Latin America, and Europe.
- Determination of Minimum Inhibitory Concentrations (MICs) using Clinical and Laboratory Standards Institute (CLSI) M27-A2 and M38-A reference methods.
- Evaluation of anidulafungin against amphotericin B, 5-fluorocytosine, fluconazole, itraconazole, ketoconazole, and voriconazole.
Main Results:
- Anidulafungin exhibited potent activity against Candida albicans, Candida tropicalis, Candida glabrata, and Candida krusei (MIC(90) ≤ 0.12 mg/L).
- Excellent activity was observed against Aspergillus spp. (Minimum Effective Concentration (MEC)(90) ≤ 0.03 mg/L).
- Anidulafungin showed reduced activity against Candida parapsilosis, Candida guilliermondii, and Candida famata (MIC(50) = 1-2 mg/L).
Conclusions:
- Anidulafungin demonstrates broad-spectrum in vitro activity against a wide array of clinically relevant yeasts and moulds.
- The findings support anidulafungin's efficacy, particularly against common Candida species and Aspergillus, aligning with previous studies.
- This surveillance data reinforces anidulafungin's potential as a valuable therapeutic option for invasive fungal infections.